「fid」の検索結果

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Nonlinear curve fitting for physics data with proper error propagation, chi-squared analysis, residual diagnostics, confidence intervals, and model comparison (AIC/BIC). Use for any parameter extraction from experimental or simulation data.

日本語の概要は準備中です。原文の説明を表示しています。

Orchestrates the untargeted LC-MS metabolomics pipeline end-to-end (xcms 4.x feature extraction, QC/drift/normalization, confidence-stratified annotation, permutation-validated statistics, background-aware pathway mapping), naming what each stage decides and where it silently fails. Use when running a full LC-MS metabolomics study from raw mzML to enriched pathways and needing the honest handoffs between stages. Each stage defers to its component skill for parameters and traps; for stable-isotope flux (a separate branch, not this untargeted flow) see metabolomics/isotope-tracing.

日本語の概要は準備中です。原文の説明を表示しています。

Orchestrates the end-to-end germline short-variant pipeline from FASTQ to a filtered, normalized, benchmarked VCF, chaining QC/trim, BWA-MEM2 alignment, duplicate marking, optional BQSR, calling (bcftools/GATK HaplotypeCaller/DeepVariant/DRAGEN), normalization, site+genotype filtering, annotation, and hap.py/vcfeval benchmarking. Use when deciding the pipeline-wide reference-genome commitment (GRCh38 analysis set vs T2T, ALT/decoy handling), sequencing the steps in the defensible order (normalize BEFORE annotate, filter site- then genotype-level), choosing the calling engine and single-sample vs cohort joint-calling, picking a filtering strategy by cohort size, or benchmarking stratified within GIAB confident regions. Hands off mechanism to the variant-calling and read-alignment component skills; not a re-teach of any single step.

日本語の概要は準備中です。原文の説明を表示しています。

Protein structure prediction from sequence. ESMFold-based, single GPU, no MSA needed. Predicts 3D structures with pLDDT confidence scores for drug discovery targets.

日本語の概要は準備中です。原文の説明を表示しています。

Runs the MS-DIAL preprocessing workflow (peak picking, MS2Dec spectral deconvolution, alignment, gap-filling) and imports the alignment-result table into R or Python with honest filtering. Use when preprocessing LC-MS DDA/DIA (SWATH) raw data with MS-DIAL, deciding MS-DIAL vs XCMS, configuring the MsdialConsoleApp console run, or parsing an MS-DIAL export into a clean feature matrix. For programmatic R peak detection and the feature-table-as-artifact framing see metabolomics/xcms-preprocessing; for lipid annotation mode see metabolomics/lipidomics; for MSI-level confidence honesty see metabolomics/metabolite-annotation; for drift correction and QC see metabolomics/normalization-qc.

日本語の概要は準備中です。原文の説明を表示しています。

Assigns honest lipid annotation levels, designs class-based internal-standard quantification, and runs lipid-aware differential and enrichment analysis with lipidr, guarding against in-source-fragment phantoms, sn-position over-claims, and invalid cross-class quantification. Use when naming or canonicalizing lipid species (shorthand separators, Goslin), deciding shotgun vs RP vs HILIC LC-MS, picking internal standards (SPLASH/EquiSPLASH), interpreting MS-DIAL/LipidSearch output, or comparing lipid classes. For general feature detection see metabolomics/xcms-preprocessing and metabolomics/msdial-preprocessing; for non-lipid annotation confidence see metabolomics/metabolite-annotation; for normalization/QC see metabolomics/normalization-qc; for multivariate stats see metabolomics/statistical-analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Maps metabolomics results to biological pathways via over-representation (ORA), metabolite-set enrichment (MSEA/QEA), mummichog/PSEA on raw m/z peaks, and network-diffusion enrichment (FELLA), with correct background-set construction and honest interpretive ceilings. Use when interpreting differential metabolites or an untargeted LC-MS feature table in pathway context, choosing ORA vs MSEA vs mummichog vs topology, or setting the reference/background set. For annotation confidence levels feeding ORA see metabolomics/metabolite-annotation; for gene-set concepts see pathway-analysis/go-enrichment and pathway-analysis/gsea; for joint gene+metabolite pathways see multi-omics-integration/mofa-integration.

日本語の概要は準備中です。原文の説明を表示しています。

Generate a non-disclosure agreement PDF with party names, effective date, and standard confidentiality terms.

日本語の概要は準備中です。原文の説明を表示しています。

Client advisory communication with fiduciary tone, compliance-friendly language, and plain-language financial education

日本語の概要は準備中です。原文の説明を表示しています。

Check the terms of a specific side-work assignment offered as gyomu-itaku or freelance work in Japan, item by item: what the client has actually put in writing about the deliverable, the fee, the payment due date, what counts as out of scope, how many revisions are included, who bears expenses, who owns the result, confidentiality, and how either side can end it. Convert the fee into an effective hourly figure over the hours the work will really take including meetings, revisions and unpaid preparation, and count the days from delivery to the payment due date. Use when someone is offered or is discussing a paid side job, a freelance assignment, spot consulting, or paid trial work and wants to know what is still unwritten before starting; do not use to judge whether the fee is fair or the terms lawful, to decide whether to accept, to draft or sign the contract for the user, or to check whether their employer's rules permit side work, which is sidework-rules-check.

日本語の概要は準備中です。原文の説明を表示しています。

Check whether a user may start side work alongside their current job, by reading the employer's own rules and contract clause by clause: whether side work is prohibited, needs prior permission, or only a notification, and which duties the planned side work could touch (non-compete, confidentiality, exclusive attention to the main job, use of company assets and information, combined working hours). Separate what is confirmed in a document from what is hearsay, and produce the questions to ask the employer plus the facts an application or notification will need. Use when someone with a main job is considering side work, freelance or gyomu-itaku work, a second part-time job, or paid trial work for another company, and needs to know what their own employer's rules require first; do not use to rule on whether a clause is lawful or enforceable, to help conceal side work from an employer or avoid filing obligations, to predict whether permission will be granted, or to submit the application or contact the employer.

日本語の概要は準備中です。原文の説明を表示しています。

Check, from the employer's side, what has been put in writing before a paid Otameshi Tenshoku assignment starts under gyomu-itaku: item by item whether the deliverable, delivery date, fee and how it is calculated, payment due date, who pays, out-of-scope work, revision limits, company support, rights, confidentiality and termination are stated in a contract, purchase order or email rather than in chat or by word of mouth, count the days from delivery to payment, and find pay tied to satisfaction or hiring, unpaid or unlimited revisions and one-sided termination. Use when a hiring manager, recruiter or small-business owner is about to offer terms to a candidate, has been asked by a candidate what is still unwritten, or needs the conditions written for a platform contract screen; do not use to judge whether the terms are lawful or the fee fair, to compute withholding or consumption tax, for employment contracts, or to sign, send or conclude the contract on the user's behalf.

日本語の概要は準備中です。原文の説明を表示しています。

Assemble a Japanese shokumu-keirekisho (career history document) from an experience inventory, choosing between reverse-chronological, chronological, and skills-based layouts, mapping the target posting's requirements to the experiences that can support them, and drafting the summary, work history, skills, and self-PR so that each sentence stays within what its evidence supports and confidential details are abstracted. Use when a user wants to write or rebuild a whole shokumu-keirekisho for a specific posting or as a general version, or wants to decide which experiences to include and in what order; do not use to invent experience, numbers, titles, or qualifications, to predict whether it will pass screening, to fill in a rirekisho form, or to submit it anywhere.

日本語の概要は準備中です。原文の説明を表示しています。

Designs and ranks guide RNAs (sgRNAs) for CRISPR-Cas9/Cas12a gene knockout by scanning a target for PAM sites (NGG SpCas9, NNGRRT SaCas9, TTTV Cas12a, NG SpCas9-NG, near-PAMless SpRY), enumerating candidate spacers, applying hard filters (Pol-III TTTT terminator, 5' G, GC), ranking on-target activity with the context-appropriate model (Rule Set 2/Azimuth for U6/lentiviral, CRISPRscan for T7/embryo, DeepHF for high-fidelity variants, DeepCpf1 for Cas12a), and predicting the indel/frameshift outcome (Bae out-of-frame score, inDelphi, FORECasT, Lindel). Use when selecting sgRNAs to knock out a gene, choosing a nuclease/PAM for a constrained locus, picking which exon to target, or shortlisting guides before an off-target check. Off-target specificity, base/prime editing, and HDR donors are separate skills.

日本語の概要は準備中です。原文の説明を表示しています。

Nominates and assesses CRISPR off-target sites genome-wide. Enumerates candidate sites by mismatch and bulge tolerance with Cas-OFFinder/CRISPRitz, ranks them with the published CFD score (SpCas9-only, relative ranker) or MIT/CRISTA/energy models, runs variant-aware screening against gnomAD/individual genomes (CRISPRme), and frames the empirical genome-wide discovery assays (GUIDE-seq, CIRCLE-seq, CHANGE-seq, DISCOVER-seq, Digenome-seq) and high-fidelity nuclease choice (HiFi Cas9, Sniper-Cas9, eSpCas9, SpCas9-HF1). Use when assessing guide RNA specificity, choosing among candidate guides, screening a therapeutic guide against population variation, or planning empirical off-target validation. Distinguishes predicted vs detected vs validated. On-target activity scoring and deaminase (Cas-independent) base/prime-editor off-targets are separate skills.

日本語の概要は準備中です。原文の説明を表示しています。

Cross-method decision tree for calling hits in pooled CRISPR screens. Catalogs statistical models (MAGeCK RRA, MAGeCK MLE, BAGEL2, drugZ, JACKS, Chronos, CERES), experimental designs each is built for, failure modes outside design domain, reconciliation when methods disagree, multiple-testing and effect-size thresholds, the order of operations (count -> QC -> CN-correct -> hit-call -> validate), the second-best-sgRNA conservative rule, and consensus-hit strategy. Use when choosing among MAGeCK / BAGEL2 / drugZ / JACKS / Chronos for a given design, reconciling disagreement across two or three methods on the same screen, deciding whether to require consensus, gating downstream validation by hit-confidence tier, or interpreting unstable hit lists across reruns.

日本語の概要は準備中です。原文の説明を表示しています。

Quality control for pooled CRISPR screens covering library representation, Gini index, log-skew, replicate Pearson and Spearman concordance, essentialome precision-recall AUC against CEGv2 (Hart 2017), Cas9 cut-toxicity diagnostics, copy-number amplicon detection (Aguirre 2016 / Munoz 2016), bottleneck propagation through plasmid pool, infection, selection, and endpoint stages, MOI verification, and DepMap-style screen-quality scoring. Use when assessing screen quality before hit calling, deciding whether to repeat or rescue a screen, diagnosing low-confidence hits, choosing between MAGeCK / BAGEL2 / Chronos based on quality grade, picking a normalization strategy from QC signatures, or evaluating whether an in-vivo screen retained adequate library complexity.

日本語の概要は準備中です。原文の説明を表示しています。

Pull pre-computed ortholog calls from public databases (OrthoDB, Ensembl Compara, OMA browser, eggNOG, PANTHER, KEGG Orthology, HomoloGene) via their REST APIs. Use when orthologs are already curated upstream, when the question is "what is the X ortholog of Y" rather than "how to infer orthology de novo", when batch-mapping gene IDs across species, or when comparing the resources for consensus calls. Encodes confidence-level semantics, 1:1 vs 1:many vs many:many, HomoloGene deprecation, and when to defect to de novo computation.

日本語の概要は準備中です。原文の説明を表示しています。

Query protein-protein and gene interaction databases (STRING, BioGRID, IntAct, SIGNOR, Reactome, HuRI, HuMAP, OmniPath, ConsensusPathDB, DIP). Use when building PPI networks, choosing between physical vs functional vs genetic interactions, signed/directed vs undirected, high-throughput vs curated, picking confidence thresholds, aggregating across resources, or navigating license constraints. Encodes the database decision matrix, STRING v12 channel semantics, OmniPath as meta-database, SIGNOR for signed signaling, and per-resource rate limits.

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Reflection-first problem solving methodology for Convex development. Use before implementing any solution to ensure proper root cause analysis, 98% code confidence, and minimal change scope.

日本語の概要は準備中です。原文の説明を表示しています。